

Rex Bionics PLC

I ? . Ž ((f \$ & \$ + - , - ' \$, %
 B 5 . Ž % * (* , - * ' \$ *)
 5 1 Ž * % & ' - & , \$ \$ + \$ \$
 U W j c b 4 d f c U W j Y j b j Y g r c f g " V é a

02:29 27 Nov 2015

Rex Bionics physiotherapy trial data provides encouragement

Rex Bionics (LON:RXB) has received some positive data from a clinical trial after its robotic legs were used in physiotherapy.

The device, currently an aid mobility for wheelchair users, is being assessed for its potential to help treat people with spinal cord injuries.

Feedback from the RAPPER II investigation found that 19 of the 20 volunteers were able to complete the walk exercise protocol - a 95% success rates.

There were no adverse events, Rex also reported.

RAPPER stands for robot-assisted physiotherapy exercises with REX.

And the trial assessed the safety and feasibility of a set of customised exercises using the state-of-the-art exoskeleton.

The data was presented by Dr Andrew Nunn of the Austin Health: Royal Talbot Rehabilitation Centre, Melbourne, Australia.

Chief executive Crispin Simon said: "I am delighted by these positive results. They are a strong message to those philanthropists who are considering donating a REX to their local rehabilitation centre; and to insurance and tax-funded healthcare systems.

"With the additional questionnaires and the seven day follow-up, positive results from the next interim analysis would confirm that REX is not just about standing and walking - great though that is - but also that there is also a therapeutic effect for people who live with spinal cord injury."

The next new RAPPER II sites will be the Royal National Orthopaedic Hospital NHS Trust, in Stanmore, on the outskirts of London and Austin Health: Royal Talbot Rehabilitation Centre, Melbourne, Australia.

Share Information

Code: RXB
Listing: AIM
Sector: Investments and investor services
Website: www.rexbionics.com

Company Synopsis:

Rex Bionics (AIM: RXB) is the UK AIM-listed pioneer of the REX Robot that enhances the mobility of wheel-chair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP).

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.